 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 March 2004 | Volume 140 Issue 5 | Pages 346-355
Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C.
Objective: To assess the efficacy and safety of 24 or 48 weeks of treatment with peginterferon-
Design: Randomized, double-blind trial.
Setting: 99 international centers.
Patients: 1311 patients with chronic hepatitis C.
Intervention: Peginterferon-
Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up.
Results: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for peginterferon-
Conclusion: Treatment with peginterferon-
*Members of the PEGASYS International Study Group are listed in the Appendix.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From Henry Dunant Hospital, Athens, Greece; Instituto de Infectologia Emílio Ribas, São Paulo, Brazil; Veterans Affairs Medical Center, Long Beach, California; Mayo Clinic Scottsdale, Scottsdale, Arizona; Hospital General Universitario, Valencia, Spain; Hôpital Beaujon, Clichy, France; Georg-August-Universität Göttingen, Göttingen, Germany; Mount Sinai School of Medicine, New York, New York; North Shore University Hospital, Manhasset, New York; Ospedale San G. Battista, Universita di Torino, Torino, Italy; University Hospital, Homburg/Saar, Germany; The Scripps Clinic, La Jolla, California; Roche, Nutley, New Jersey; and Welwyn Garden City, United Kingdom.
Acknowledgments: The authors and members of the PEGASYS International Study Group thank Drs. Chris Pappas, Michael Brunda, Matei Popescu, and Joseph Hoffman of Roche for assisting with the conduct of this study and the preparation of this manuscript.
Grant Support: By Roche, Basel, Switzerland.
Potential Financial Conflicts of Interest:Employment: A. Lin (Hoffmann-La Roche), A.M. Ackrill (Roche); Consultancies: S.J. Hadziyannis (Roche), P. Marcellin, H. Bodenheimer Jr. (Roche), D. Bernstein (Roche), S. Zeuzem (Roche, Schering-Plough, Yamanouchi), P.J. Pockros (Roche); Honoraria: S.J. Hadziyannis (Bristol-Myers Squibb, Gilead, Roche, Schering-Plough), T.R. Morgan (Roche, Schering-Plough), P. Marcellin, H. Bodenheimer Jr. (Roche, Schering), D. Bernstein (Roche), S. Zeuzem (Roche, Schering-Plough, Yamanouchi), P.J. Pockros (Roche); Grants received: T.R. Morgan (Roche, Schering-Plough), V. Balan (Roche), H. Bodenheimer Jr. (Roche, Schering), D. Bernstein (Roche), S. Zeuzem (Roche, Schering-Plough, Yamanouchi), P.J. Pockros (Roche); Grants pending: T.R. Morgan (Roche, Schering-Plough), V. Balan (Roche), P.J. Pockros (Roche).
Requests for Single Reprints: Stephanos J. Hadziyannis, MD, Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Mesoghion Avenue, Athens, Greece 11526; e-mail, hadziyannis{at}ath.forthnet.gr.
Current Author Addresses: Dr. Hadziyannis: Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Mesoghion Avenue, Athens, Greece 11526.
Dr. Sette: Instituto de Infectologia "Emilio Ribas," Ambulatorio de Hepatologi, Av. Dr. Arnaldo 165, São Paulo, SP, Brazil 01239-040.
Dr. Morgan: Veterans Affairs Medical Center, 111G, 5901 East Seventh Street, Long Beach, CA 90822.
Dr. Balan: Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054.
Dr. Diago: Hospital General de Valencia, Av. Tres Cruces s/n, Valencia, Spain 46014.
Dr. Marcellin: Hôpital Beaujon, 100 Boulevard du General Leclerc, Clichy, France 82110.
Dr. Ramadori: Universitätsklinik Göttingen, Zentrum Innere Medizin, Robert-Koch Strasse 40, Göttingen, Germany 37075.
Dr. Bodenheimer: Mount Sinai Medical Center, 1 Gustave L. Levy Place Atran 708, Box 1633, New York, NY 10029-6574.
Dr. Bernstein: North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030.
Dr. Rizzetto: University of Torino, Corso Bramante 88, Torino, Italy 10126.
Dr. Zeuzem: University Hospital, Department of Internal Medicine II, D-66421 Homburg/Saar, Germany.
Dr. Pockros: The Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037.
Dr. Lin: Hoffmann-La Roche, 340 Kingsland Street, Nutley, NJ 07110.
Dr. Ackrill: Roche Products Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire, United Kingdom AL7 3AY.
Author Contributions: Conception and design: S.J. Hadziyannis, A. Lin, A.M. Ackrill.
Analysis and interpretation of the data: S.J. Hadziyannis, T.R. Morgan, P. Marcellin, S. Zeuzem, A. Lin, A.M. Ackrill.
Drafting of the article: S.J. Hadziyannis, D. Bernstein, S. Zeuzem, A. Lin, A.M. Ackrill.
Critical revision of the article for important intellectual content: S.J. Hadziyannis, T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, S. Zeuzem, P.J. Pockros, A. Lin, A.M. Ackrill.
Final approval of the article: S.J. Hadziyannis, T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, S. Zeuzem, P.J. Pockros, A. Lin, A.M. Ackrill.
Provision of study materials or patients: H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P.J. Pockros.
Statistical expertise: A. Lin.
Collection and assembly of data: S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, H. Bodenheimer Jr., S. Zeuzem, A. Lin. ARTICLE
Peginterferon-
2a and Ribavirin Combination Therapy in Chronic Hepatitis C
A Randomized Study of Treatment Duration and Ribavirin Dose
2a plus a low or standard dose of ribavirin. 2a, 180 µg/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. 2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. 2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
2a plus standard doses of ribavirin (1000 or 1200 mg/d) led to sustained virologic responses more often than did 24-week treatment and combination therapy with low-dose ribavirin. Longer treatment duration and higher ribavirin dose was not necessary in patients with genotype 2 or 3.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Huckans, A. Mitchell, S. Ruimy, J. Loftis, and P. Hauser Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia Schizophr Bull, June 17, 2008; (2008) sbn065v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sarasin-Filipowicz, E. J. Oakeley, F. H. T. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M. H. Heim Interferon signaling and treatment outcome in chronic hepatitis C PNAS, May 13, 2008; 105(19): 7034 - 7039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Woodhouse, C. Smith, M. Michelet, N. Branza-Nichita, M. Hussey, R. A. Dwek, and N. Zitzmann Iminosugars in Combination with Interferon and Ribavirin Permanently Eradicate Noncytopathic Bovine Viral Diarrhea Virus from Persistently Infected Cells Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1820 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aguilar Marucco, D. Gonzalez de Requena, S. Bonora, C. Tettoni, M. Bonasso, T. De Blasi, A. D'Avolio, M. Sciandra, M. Siccardi, L. Baietto, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon J. Antimicrob. Chemother., April 1, 2008; 61(4): 919 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree? Med Decis Making, April 1, 2008; 28(2): 233 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 T Asselah, I Bieche, S Narguet, A Sabbagh, I Laurendeau, M-P Ripault, N Boyer, M Martinot-Peignoux, D Valla, M Vidaud, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut, April 1, 2008; 57(4): 516 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T J S Cross, C G Antoniades, and P M Harrison Current and future management of chronic hepatitis C infection Postgrad. Med. J., April 1, 2008; 84(990): 172 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Shi, K. J. Herlihy, J. P. Graham, S. A. Fuhrman, C. Doan, H. Parge, M. Hickey, J. Gao, X. Yu, F. Chau, et al. In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Antimicrob. Agents Chemother., February 1, 2008; 52(2): 675 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Pineda, J. A. Mira, I. d. l. S. Gil, B. Valera-Bestard, A. Rivero, D. Merino, J. A. Giron-Gonzalez, M. J. Rios-Villegas, M. Gonzalez-Serrano, A. Collado, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients J. Antimicrob. Chemother., December 1, 2007; 60(6): 1347 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ma, W.-R. Jiang, N. Robledo, V. Leveque, S. Ali, T. Lara-Jaime, M. Masjedizadeh, D. B. Smith, N. Cammack, K. Klumpp, et al. Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species J. Biol. Chem., October 12, 2007; 282(41): 29812 - 29820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tuaillon, A.-M. Mondain, L. Ottomani, L. Roudiere, P. Perney, M.-C. Picot, F. Seguret, F. Blanc, D. Larrey, P. Van de Perre, et al. Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA Assay J. Clin. Microbiol., September 1, 2007; 45(9): 3077 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ticehurst, F. M. Hamzeh, and D. L. Thomas Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis J. Clin. Microbiol., August 1, 2007; 45(8): 2426 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lindh, E. Alestig, B. Arnholm, A. Eilard, K. Hellstrand, M. Lagging, T. Wahlberg, R. Wejstal, J. Westin, and G. Norkrans Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection J. Clin. Microbiol., August 1, 2007; 45(8): 2439 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Donlin, N. A. Cannon, E. Yao, J. Li, A. Wahed, M. W. Taylor, S. H. Belle, A. M. Di Bisceglie, R. Aurora, J. E. Tavis, et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy J. Virol., August 1, 2007; 81(15): 8211 - 8224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chevaliez, R. Brillet, E. Lazaro, C. Hezode, and J.-M. Pawlotsky Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection J. Virol., July 15, 2007; 81(14): 7732 - 7741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Shiffman, F. Suter, B. R. Bacon, D. Nelson, H. Harley, R. Sola, S. D. Shafran, K. Barange, A. Lin, A. Soman, et al. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 N. Engl. J. Med., July 12, 2007; 357(2): 124 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yano, M. Ikeda, K.-i. Abe, H. Dansako, S. Ohkoshi, Y. Aoyagi, and N. Kato Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2016 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Gupta, E. Sellers, E. Somoza, L. Angles, K. Kolz, and D. L. Cutler The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy J. Clin. Pharmacol., May 1, 2007; 47(5): 604 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Koziel and M. G. Peters Viral Hepatitis in HIV Infection N. Engl. J. Med., April 5, 2007; 356(14): 1445 - 1454. [Full Text] [PDF]
|
|
|
|
|
|
M. W. Taylor, T. Tsukahara, L. Brodsky, J. Schaley, C. Sanda, M. J. Stephens, J. N. McClintick, H. J. Edenberg, L. Li, J. E. Tavis, et al. Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy J. Virol., April 1, 2007; 81(7): 3391 - 3401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Yu, C.-Y. Dai, J.-F. Huang, N.-J. Hou, L.-P. Lee, M.-Y. Hsieh, C.-F. Chiu, Z.-Y. Lin, S.-C. Chen, M.-Y. Hsieh, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Gut, April 1, 2007; 56(4): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A Butt, A. C Justice, M. Skanderson, M. O Rigsby, C. B Good, and C K. Kwoh Rate and predictors of treatment prescription for hepatitis C Gut, March 1, 2007; 56(3): 385 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Scott and D. R. Gretch Molecular Diagnostics of Hepatitis C Virus Infection: A Systematic Review JAMA, February 21, 2007; 297(7): 724 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E D. Santos, N. Partovi, J.-A. E Ford, and E. M Yoshida Use of Hematopoietic Growth Factors as Adjuvant Therapy for Anemia and Neutropenia in the Treatment of Hepatitis C Ann. Pharmacother., February 1, 2007; 41(2): 268 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Agarwal, T. J S Cross, and C. Gore Chronic hepatitis C BMJ, January 13, 2007; 334(7584): 54 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wohnsland, W. P. Hofmann, and C. Sarrazin Viral Determinants of Resistance to Treatment in Patients with Hepatitis C Clin. Microbiol. Rev., January 1, 2007; 20(1): 23 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liu, K. Abid, J. Pichardo, V. Pazienza, P. Ingravallo, R. Kong, S. Agrawal, S. Bogen, A. Saksena, K.-C. Cheng, et al. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease J. Antimicrob. Chemother., January 1, 2007; 59(1): 51 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Hoofnagle and L. B. Seeff Peginterferon and Ribavirin for Chronic Hepatitis C N. Engl. J. Med., December 7, 2006; 355(23): 2444 - 2451. [Full Text] [PDF]
|
|
|
|
|
|
H. Dutartre, C. Bussetta, J. Boretto, and B. Canard General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4161 - 4169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Sherman, E M Yoshida, M Deschenes, M Krajden, V G Bain, K Peltekian, F Anderson, K Kaita, S Simonyi, R Balshaw, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut, November 1, 2006; 55(11): 1631 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Horsmans Interferon-induced depression in chronic hepatitis C J. Antimicrob. Chemother., October 1, 2006; 58(4): 711 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Jones, L. E. Clancy, W. D. Rawlinson, and P. A. White High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3019 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M P Manns, H Wedemeyer, and M Cornberg Treating viral hepatitis C: efficacy, side effects, and complications. Gut, September 1, 2006; 55(9): 1350 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Chang, Z. Cai, C. Zhang, G. C. Sen, B. R. G. Williams, and G. Luo Replication of Hepatitis C Virus (HCV) RNA in Mouse Embryonic Fibroblasts: Protein Kinase R (PKR)-Dependent and PKR-Independent Mechanisms for Controlling HCV RNA Replication and Mediating Interferon Activities. J. Virol., August 1, 2006; 80(15): 7364 - 7374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Lee and T. Wong Hepatitis C: reviewing the options. Can. Med. Assoc. J., July 4, 2006; 175(1): 64 - 64. [Full Text] [PDF]
|
|
|
|
|
|
P. Halfon, M. Bourliere, G. Penaranda, H. Khiri, and D. Ouzan Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J. Clin. Microbiol., July 1, 2006; 44(7): 2507 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Patel, A. J Muir, and J. G McHutchison Diagnosis and treatment of chronic hepatitis C infection. BMJ, April 29, 2006; 332(7548): 1013 - 1017. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rifai, J. K. Moles, and D. D. Short Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness Psychiatr Serv, April 1, 2006; 57(4): 570 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, et al. Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease Antimicrob. Agents Chemother., March 1, 2006; 50(3): 899 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sarrazin, B. C. Gartner, D. Sizmann, R. Babiel, U. Mihm, W. P. Hofmann, M. von Wagner, and S. Zeuzem Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5. J. Clin. Microbiol., March 1, 2006; 44(3): 729 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rifai, J. K. Moles, L. P. Lehman, and B. J. Van der Linden Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics, March 1, 2006; 47(2): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Diago, G Castellano, J Garcia-Samaniego, C Perez, I Fernandez, M Romero, O L Iacono, and C Garcia-Monzon Association of pretreatment serum interferon {gamma} inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C Gut, March 1, 2006; 55(3): 374 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A Hughes and S. D Shafran Treatment of Hepatitis C in HIV-Coinfected Patients Ann. Pharmacother., March 1, 2006; 40(3): 479 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wong and S. S. Lee Hepatitis C: a review for primary care physicians Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. McNelis Management of Hepatitis C Infection in the HIV-Infected Patient Journal of Pharmacy Practice, February 1, 2006; 19(1): 37 - 52. [Abstract] [PDF]
|
|
|
|
|
|
C. A Hughes and S. D Shafran Chronic Hepatitis C Virus Management: 2000-2005 Update Ann. Pharmacother., January 1, 2006; 40(1): 74 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Brau Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy J. Antimicrob. Chemother., December 1, 2005; 56(6): 991 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hazari, A. Patil, V. Joshi, D. E. Sullivan, C. D. Fermin, R. F. Garry, R. M. Elliott, and S. Dash Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes J. Gen. Virol., November 1, 2005; 86(11): 3047 - 3053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Brok, L. L. Gluud, and C. Gluud Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection: A Systematic Review and Meta-analysis of Randomized Trials Arch Intern Med, October 24, 2005; 165(19): 2206 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rodriguez-Torres, F. J. Torriani, V. Soriano, M. J. Borucki, E. Lissen, M. Sulkowski, D. Dieterich, K. Wang, J.-M. Gries, P. G. Hoggard, et al. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study Antimicrob. Agents Chemother., October 1, 2005; 49(10): 3997 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Naka, K. Takemoto, K.-i. Abe, H. Dansako, M. Ikeda, K. Shimotohno, and N. Kato Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors J. Gen. Virol., October 1, 2005; 86(10): 2787 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rodriguez-Inigo, J. M. Lopez-Alcorocho, J. Bartolome, N. Ortiz-Movilla, M. Pardo, and V. Carreno Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels J. Mol. Diagn., October 1, 2005; 7(4): 535 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mangia, R. Santoro, N. Minerva, G. L. Ricci, V. Carretta, M. Persico, F. Vinelli, G. Scotto, D. Bacca, M. Annese, et al. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 N. Engl. J. Med., June 23, 2005; 352(25): 2609 - 2617. [Abstract] [Full Text] [PDF]
|
Article
